# PD 0332991 and Cetuximab in Patients With Incurable SCCHN

> **NCT02101034** · PHASE1,PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 96 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** PD 0332991

## Key facts

- **NCT ID:** NCT02101034
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-17
- **Primary completion:** 2020-06-08
- **Final completion:** 2023-11-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101034, "PD 0332991 and Cetuximab in Patients With Incurable SCCHN". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02101034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*